Brentuximab vedotin in CD30+lymphomas: single center experience

被引：0
|
作者：
Aydin, M. [1 ]
Okay, M. [2 ]
Ciftciler, R. [2 ]
Aladag, E. [2 ]
Aksu, S. [2 ]
Demiroglu, H. [2 ]
Goker, H. [2 ]
Buyukasik, Y. [2 ]
Ozcebe, O. [2 ]
Haznedaroglu, I. [2 ]
Sayinalp, N. [2 ]
机构：
[1] Ankara Numune Training & Res Hosp, Ankara, Turkey
[2] Hacettepe Univ Hematol, Ankara, Turkey
来源：
LEUKEMIA RESEARCH | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP-50
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [31] A pilot study of weekly brentuximab vedotin in patients with CD30+malignancies resistant to brentuximab vedotin every 3 weeks
    Poston, Jacqueline N.
    Fromm, Jonathan R.
    Rasmussen, Heather A.
    Shustov, Andrei R.
    Libby, Edward N., III
    Smith, Stephen D.
    Gooley, Ted
    Gopal, Ajay K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) : 159 - 162
  • [32] Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data
    Enos, Tyler H.
    Feigenbaum, Lawrence S.
    Wickless, Heather W.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (12) : 1400 - 1405
  • [33] Therapeutic Use of Brentuximab Vedotin in CD30+Hematologic Malignancies
    Fabbri, Alberto
    Cencini, Emanuele
    Gozzetti, Alessandro
    Schiattone, Luana
    Bocchia, Monica
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (07) : 886 - 895
  • [34] CD30 Expression Does Not Predict Response To Brentuximab Vedotin
    Xu, Mina
    Katz, Samuel
    MODERN PATHOLOGY, 2015, 28 : 389A - 389A
  • [35] Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
    Lesley J. Scott
    Drugs, 2017, 77 : 435 - 445
  • [36] SOLUBLE CD30 LEVELS UNDER BRENTUXIMAB VEDOTIN THERAPY
    Porpaczy, E.
    Schiefer, A.
    Olah, N.
    Skrabs, C.
    Krauth, M.
    Knoebl, P.
    Hauswirth, A.
    Sperr, W.
    Reichmann, S.
    Schneeweiss, M.
    Knapp, S.
    Vanura, K.
    Jaeger, U.
    HAEMATOLOGICA, 2013, 98 : 69 - 70
  • [37] Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
    Scott, Lesley J.
    DRUGS, 2017, 77 (04) : 435 - 445
  • [38] Clinical Responses to CAR.CD30-T Cells in Patients With CD30+ Lymphomas Relapsed After Multiple Treatments Including Brentuximab Vedotin
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 14 - 15
  • [39] Expression of CD30 as a biomarker to predict response to brentuximab vedotin
    Xu, Mina L.
    Acevedo-Gadea, Carlos
    Seropian, Stuart
    Katz, Samuel G.
    HISTOPATHOLOGY, 2016, 69 (01) : 155 - 158
  • [40] CD30 Expression Does Not Predict Response To Brentuximab Vedotin
    Xu, Mina
    Katz, Samuel
    LABORATORY INVESTIGATION, 2015, 95 : 389A - 389A
12345